Markets
2023 WSJ's Future Of Everything Festival
NEW YORK, NEW YORK - MAY 02: Nick Timiraos, Richard Clarida, and Michelle Meyer attend 2023 WSJ's Future Of Everything Festiva (Photo by Joy Malone/Getty Images)
50 you hot

The market is listening to the media

The odds of a 50 basis point rate cut at this week's Fed meeting continue to creep higher.

Luke Kawa

The pen is mightier than the trading floor’d.

Articles published by prominent journalists who cover the Federal Reserve last week, most notably the Wall Street Journal’s Nick Timiraos, are continuing to prompt a significant re-evaluation of how much the US central bank will cut interest rates this week.

After a so-so monthly increase in the core consumer price index for August, the odds of a 50 basis point rate reduction this week went below 15%. On Monday morning, the likelihood of a cut that large is approaching 70%.

“The Committee is certainly cognizant of the market’s expectations and in the event that a 50 basis point cut is more than 80% priced in, such a move might be the Fed’s decision to prevent a sharp selloff in risk assets,” writes BMO Capital Markets head of US rates strategy Ian Lyngen.

This Deutsche Bank chart from a note published Friday shows just how unusual it is for a Federal Reserve meeting to have this much uncertainty this close to the event. Except now on Monday morning, the state of affairs is flipped – it would be more surprising if the central bank cut by only 25 basis points.

DBmarketsurprise
Source: X via @jeuasommenulle

The central bank using a high-profile media contact (often at the Wall Street Journal) to guide the market in a certain direction during the “blackout period” in which US monetary policymakers are unable to speak to the public would not be a new phenomenon. The June 13, 2022 article from Nick Timiraos (“Fed likely to consider 0.75-percentage-point rate rise this week”) stands out. Market pricing implied traders thought there was less than a 30% chance of that outcome before that was published; by the end of the next trading day, the odds of a 75 basis point hike were priced at 90%. 

In a separate report, Deutsche Bank economists even turned to their proprietary artificial intelligence tool to analyze the language used in last week’s article compared to Timiraos’ pointed message from June 2022. 

The AI results suggested that the June 2022 article’s tone was “urgent and decisive,” suggesting high conviction in the result being prophesied. The more recent post, on the other hand, was “balanced and analytical” with “moderate to low” conviction. 

“While there were echoes of that earlier period in this week’s reporting, we also felt that the level of conviction was greater in the June 2022 articles,” write Deutsche Bank economists led by Matthew Luzzetti. “While we know AI results can be inaccurate or subject to criticism, the sentiment analysis from DB’s tool matches our own perception of the conviction level of each article.”

Of course, while media missives appear to be playing the dominant role, there may be more to the massive repricing. After the producer price index and import data that were released following August’s CPI report, inflation forecasters generally expect that the Federal Reserve’s preferred gauge of inflation (released near the end of the month) will have gone up at a very modest pace last month. 

More Markets

See all Markets
markets

Trump administration says tariffs on Chinese semiconductor imports are coming... in 2027

After a year-long investigation into China’s tactics to bolster its domestic semiconductor industry, the US has determined that its practices are “unreasonable” and is going to do something about that in 18 months.

The Trump administration’s office of the US trade representative said today that it plans to impose tariffs on imports of Chinese semiconductors at a rate higher than 0% to be decided at least 30 days before June 23, 2027.

“China’s pursuit of its dominance goals has severely disadvantaged US companies, workers, and the U.S. economy generally through lessened competition and commercial opportunities and through the creation of economic security risks from dependencies and vulnerabilities,” per the USTR’s notice of action.

These levies, should they come to pass, would apply to silicon, diodes, transistors, and more.

US markets were completely unbothered by this revelation, likely because there is no immediate action against Chinese semi companies and therefore no disruption to business-as-usual. This represents a punting of a contentious matter, similar to how China delayed restrictions on rare earth shipments as part of a deal between Presidents Trump and Xi following their October meeting.

It’s another sign of a thaw in the US-China relations over the hot-button issue of semiconductors after President Trump gave Nvidia the go-ahead to sell its H200 chips to buyers in the world’s second-largest economy.

markets

ServiceNow strikes deal to buy cybersecurity firm Armis for $7.75 billion in cash

ServiceNow has agreed to acquire cybersecurity startup Armis for $7.75 billion in an all-cash deal, the largest purchase in the company's history.

That price tag is $750 million above what Bloomberg suggested was the top end of what Armis would cost just last week, and about $1.65 billion above what the company had been valued at in a November funding round.

Armis had been readying itself for an IPO, with many major investors looking to take a stake in the firm.

Instead, it’s now a key cog in the software platform company’s bid to lean on cybersecurity features to bolster its appeal to customers in a world in which the rise of AI adds to the potential threats of business disruptions and data breaches.

Per the press release:

As rapid AI adoption expands the attack surface for organizations, real-time visibility into vulnerabilities and actionable insights for what to fix first are critical to minimize risk and strengthen security posture. The acquisition of Armis will extend and enhance ServiceNow’s Security, Risk, and OT portfolios in critical and fast-growing areas of cybersecurity and drive increased AI adoption by strengthening trust across businesses’ connected environments.

markets

Novo Nordisk rallies after FDA weight loss pill approval

Novo Nordisk’s US-listed shares are up 7% in pre-market trading on Tuesday after the US Food and Drug Administration approved its Wegovy weight loss pill on Monday evening.

Now the first pill of its kind to receive approval from the regulator, Novo’s Wegovy pill is expected to launch in the US in early January 2026, and awaits the European Medicines Agency and other regulatory authorities’ approval after submitting for review in the second half of 2025, per the company’s press release. The 1.5 milligram starting dose of the pill will be sold at an introductory price of $149 a month.

“The pill is here. With today's approval of the Wegovy® pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy® injection,” said Mike Doustdar, president and CEO of Novo Nordisk.

The approval was based on Novo’s Oasis 4 trial, which found participants who took 25 milligram doses of Wegovy pills daily lost 16.6% of their body weight over a 64 week period.

The approval will give Novo — which lost more than 50% of its market cap this year after Eli Lilly took the crown in weekly US prescriptions for injectable weight-loss drugs with its product Zepbound — a first-mover advantage in the expanding market. Lilly, which is down some 1% in pre-market trading today, has said its own oral drug orforglipron could be approved by March 2026.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.